Tadalafil Tablet, Film Coated
Product Images NDC 72865-107

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 72865-107). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tadalafil10mglabel (Tadalafil10mglabel)

Label for Tadalafil Tablets USP 10 mg oral film-coated tablets manufactured for XLCare Pharmaceuticals Inc. The label shows the NDC 72865-107-30 and indicates a package size of 30 tablets. It includes storage instructions, a warning to keep out of reach of children, and manufacturer information for Evaric Pharmaceuticals Inc.*

FDA Label Image

Tadalafil20mglabel (Tadalafil20mglabel)

Tadalafil 20 mg film-coated tablets label by XLCare Pharmaceuticals Inc. The label includes the proprietary name, strength, dosage form, and quantity of 30 tablets. It provides storage instructions, a warning to keep out of reach of children, and contact information. Manufactured by Evaric Pharmaceuticals Inc.*

FDA Label Image

Tadalafil25mglabel (Tadalafil25mglabel)

Label of Tadalafil Tablets, USP 2.5 mg oral film-coated tablets by XLCare Pharmaceuticals Inc. The label highlights the 2.5 mg strength, packaging size of 30 tablets, and states Rx only. It includes usage instructions to take one tablet daily, storage conditions, and manufacturer information including Evaric Pharmaceuticals Inc. with contact details.*

FDA Label Image

Tadalafil5mglabel (Tadalafil5mglabel)

Label for Tadalafil Tablets, USP 5 mg, film-coated oral tablets. The label states there are 30 tablets per package. It is manufactured for XL Care Pharmaceuticals Inc. and by Evaric Pharmaceuticals Inc. The label includes dosage information, warning to keep out of reach of children, storage instructions, and contact details.*

FDA Label Image

Tadalafilfigure1 (Tadalafilfigure1)

A set of four line graphs illustrating the difference in blood pressure measurements (Tadalafil minus Placebo) over time in hours. The panels show changes in standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure, each with time on the x-axis and difference in mmHg on the y-axis, including error bars.*

FDA Label Image

Tadalafilfigure2 (Tadalafilfigure2)

This figure consists of two line graphs displaying the effects of Tadalafil 20 mg combined with doxazosin 8 mg versus placebo with doxazosin 8 mg on systolic blood pressure over 24 hours post-dose. The top graph shows standing systolic blood pressure (mmHg) measurements, and the bottom graph shows supine systolic blood pressure (mmHg) changes over time.*

FDA Label Image

Tadalafilfigure3 (Tadalafilfigure3)

Line graph depicting systolic blood pressure (mmHg) changes over 12 hours after administration of 20 mg tadalafil or placebo, each combined with 8 mg doxazosin at 08:00 and 20:00. Four lines represent different dosing times and treatments, showing blood pressure trends post-administration.*

FDA Label Image

Tadalafilfigure4 (Tadalafilfigure4)

Line chart showing plasma tadalafil concentration (µg/L) over time (hours) for different dosing regimens: a single 20 mg dose, a single 5 mg dose, and once-daily 5 mg doses following 5 consecutive days of administration. The graph includes error bars representing variability at each time point.*

FDA Label Image

Tadalafilfigure5 (Tadalafilfigure5)

A line graph showing mean IPSS (International Prostate Symptom Score) changes from baseline in BPH patients over 12 weeks of treatment. The x-axis represents duration of treatment in weeks (0, 4, 8, 12), and the y-axis shows change from baseline in IPSS total score, ranging from 0 to -6. Two lines compare Tadalafil 5 mg and placebo, with Tadalafil showing a greater decrease in IPSS score over time.*

FDA Label Image

Tadalafilfigure6 (Tadalafilfigure6)

A line graph titled 'Mean IPSS Changes in BPH Patients by Visit in Study K' showing the change from baseline in IPSS total score over a 12-week treatment duration. The graph compares two groups: patients treated with Tadalafil 5 mg and those given a placebo, indicating greater score reductions for the Tadalafil group over time with statistical significance marked (p<0.01).*

FDA Label Image

Tadalafilfigure7 (Tadalafilfigure7)

This is a line graph depicting the least-squares mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride and Placebo/Finasteride groups. The x-axis shows weeks of therapy (0, 4, 12, 26) and the y-axis shows LS mean change from baseline (0 to -7). Two lines represent the treatment groups, with vertical arrows indicating least-squares treatment differences at 4, 12, and 26 weeks, along with significance annotations (p<0.001 and p<0.05).*

FDA Label Image

Tadalafilfigure8 (Tadalafilfigure8)

A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment for Tadalafil versus placebo. The graph shows greater decline in scores for Tadalafil, indicating improvement, with markers at 0, 2, 4, 8, and 12 weeks. Statistical significance is noted at 12 weeks (p<0.01).*

FDA Label Image

Tadalafilstructure (Tadalafilstructure)

Chemical structure of Tadalafil, showing its molecular framework with fused rings and various functional groups as depicted in the image.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.